Biomagnetic Technologies is soliciting additional equity capital to help the company stave off a looming cash shortage that could hurt the company's ability to continue operating beyond the end of February. The San Diego-based magnetic source imaging
Biomagnetic Technologies is soliciting additional equity capital to help the company stave off a looming cash shortage that could hurt the company's ability to continue operating beyond the end of February. The San Diego-based magnetic source imaging developer reported that cash is running out even as the company reported improved financial results for fiscal 1997 (end-September).
BTI announced on Jan. 15 that its cash resources would be exhausted by the end of next month. To shore up its cash position, BTI is seeking equity investment from international investors, and has already received $2.8 million from the sale of 5.5 million shares of newly issued stock. Of that investment, some $2 million was used in a debt-for-equity swap with BTI shareholder Dassesta International of Switzerland.
Ironically, BTI reported sharply improved financial results for 1997 as the company recognized revenue from long-delayed shipments of its Magnes 2500 Whole Head system. BTI reported revenues of $10.6 million, compared with $733,000 in 1996. The company's net loss for 1997 shrank to $5.2 million, compared with $15.6 million the year before.
Despite the cash shortage, BTI chairman Enrique Maso said the company made progress last year, finishing the Whole Head system and improving the clinical and economic rationale for magnetic source imaging. Maso said he is confident that BTI will be able to raise the funds needed to continue operating.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.